GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Petra Acquisition Inc (NAS:PAICW) » Definitions » PensionAndRetirementBenefit

Switch to:

PAICW (Petra Acquisition) PensionAndRetirementBenefit : $0.00 Mil (As of Sep. 2021)

View and export this data going back to 2020. Start your Free Trial

What is Petra Acquisition PensionAndRetirementBenefit?

Petra Acquisition's PensionAndRetirementBenefit for the quarter that ended in Sep. 2021 was $0.00 Mil.

Petra Acquisition PensionAndRetirementBenefit Historical Data

The historical data trend for Petra Acquisition's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petra Acquisition PensionAndRetirementBenefit Chart

Petra Acquisition Annual Data

Trend

Dec19

Dec20

PensionAndRetirementBenefit

-

-

Petra Acquisition Semi-Annual Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
PensionAndRetirementBenefit	Get a 7-Day Free Trial			-	-	-	-	-

Petra Acquisition PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Petra Acquisition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Petra Acquisition Inc (NAS:PAICW) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 West 21st Street, New York, NY, USA, 10010

Website

Petra Acquisition Inc is a blank check company.

Petra Acquisition Headlines

From GuruFocus

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

By Marketwired Marketwired • 09-28-2021

Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company's Diagnostic Tool, REVID�

By Marketwired Marketwired • 11-01-2021

Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board

By GuruFocusNews GuruFocusNews • 11-29-2021

Petra Acquisition Inc. Announces Closing of $70 Million Initial Public Offering

By GlobeNewswire GlobeNewswire • 10-13-2020

Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination

By GuruFocusNews GuruFocusNews • 12-22-2021

Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

By Marketwired Marketwired • 10-25-2021

Petra Acquisition Inc. Announces Closing of $70 Million Initial Public Offering

By Marketwired Marketwired • 10-14-2020

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

By Don Li2 Don Li2 • 11-15-2021

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

By Marketwired Marketwired • 10-04-2021

PETRA ACQUISITION, INC. ANNOUNCES SECURITIES TO COMMENCE SEPARATE TRADING

By Marketwired Marketwired • 11-10-2020

Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Partner Program FAQ Contact Us 中文 All-In-One Screener
Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.